UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
September 2023
Commission File Number: 001-41386
OKYO
Pharma LTD
(Exact Name of Registrant as Specified in Its Charter)
9th Floor
107 Cheapside
London
EC2V 6DN
(Address of registrant’s principal executive
office)
Indicate by check mark whether the registrant files
or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K
On September 13, 2023, OKYO Pharma LTD (the “Company”)
issued this 6K announcing, that that it intends to offer to sell its ordinary shares in an underwritten public offering (the “Offering”).
All of the ordinary shares are to be sold by the Company. The Company expects to grant the underwriter a 30-day option to purchase up
to an additional 15% of the number of ordinary shares sold in this Offering to cover over-allotments, if any. The Offering is subject
to market conditions and there can be no assurance as to whether or when the Offering may be completed, or as to the actual size or terms
of the Offering., a copy of which is furnished as Exhibit 99.1
The Announcement is furnished herewith as Exhibit
99.1 to this Report on Form 6-K. The information in the attached Exhibits 99.1 is being furnished and shall not be deemed “filed”
for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that Section, nor shall
it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Securities
Exchange Act of 1934, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing.
SIGNATURES
Pursuant to the requirements of the Securities Exchange
Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
OKYO Pharma LTD |
|
|
|
Date: September 13, 2023 |
By: |
/s/ Keeren Shah |
|
Name: |
Keeren Shah |
|
Title: |
Chief Financial Officer |
EXHIBIT INDEX
Exhibit 99.1
OKYO Pharma Announces Public Offering of Ordinary
Shares
London and New York, NY – September 13, 2023
– OKYO Pharma Limited (Nasdaq: OKYO) (“OKYO” or the “Company”), an ophthalmology-focused bio-pharmaceutical
company which is developing OK-101 to treat dry eye disease (“DED”), today announced that it intends to offer to sell its
ordinary shares in an underwritten public offering (the “Offering”). All of the ordinary shares are to be sold by the Company.
The Company expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the number of ordinary shares sold
in this Offering to cover over-allotments, if any. The Offering is subject to market conditions and there can be no assurance as to whether
or when the Offering may be completed, or as to the actual size or terms of the Offering.
Freedom Capital Markets is acting as the sole book-running
manager for the Offering. Bancroft Capital is acting as co-manager.
OKYO intends to use the net proceeds from the Offering
primarily for clinical development of the Company’s product candidates, general corporate purposes and working capital.
The Company has received indications of interest from
a limited number of individual and institutional investors to purchase up to $4.0 million of our ordinary shares in a Company best efforts
registered direct offering, which if concluded would price and close at or about the same time as this Offering. Any shares sold by us
in the registered direct offering would be at the same price per share to the public as those sold in this Offering. The consummation
of this Offering is not conditioned on the consummation of the registered direct offering, and neither is such offering contingent on
this Offering, and the Company cannot provide any assurance that the proposed registered direct offering will price or close regardless
of whether this Offering prices and closes.
The securities are being offered and
sold pursuant to a shelf registration statement on Form F-3 (File No. 333-272516), including a base prospectus, filed with the U.S. Securities
and Exchange Commission (the “SEC”) on June 8, 2023, and declared effective on June 14, 2023. The
Offering is being made only by means of a prospectus supplement and the accompanying base prospectus, as may be further supplemented
by any free writing prospectus and/or pricing supplement that the Company may file with the SEC. A preliminary prospectus supplement
and the accompanying base prospectus describing the terms of the proposed Offering have been filed with the SEC and are available on
the SEC’s website at www.sec.gov. The final prospectus supplement relating to the Offering will be filed with the SEC and
will also be available on the SEC’s website. Copies of the preliminary prospectus supplement, the final prospectus supplement and
the accompanying base prospectus relating to the Offering can also be obtained, when available, in writing from Freedom Capital Markets,
40 Wall Street, 58th Floor, New York, NY 10005, or via email at EquitySyndicate@freedomcapmkts.com and via telephone at (800)
786-1469.
This press release shall not constitute an offer to
sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such
offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.
About OKYO Pharma
OKYO Pharma Limited (Nasdaq: OKYO) is a life sciences
company, focusing on the discovery and development of novel molecules to treat inflammatory dry eye diseases and chronic pain.
Forward-Looking Statements
Statements in this press
release may be “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause
actual results to differ materially from those anticipated or projected in the forward-looking statements. These forward-looking
statements are not historical facts but rather are based on the Company’s current expectations, estimates, and projections about
its industry; its beliefs; and assumptions. Words such as ‘anticipates,’ ‘expects,’ ‘intends,’ ‘plans,’
‘believes,’ ‘seeks,’ ‘estimates,’ and similar expressions are intended to identify forward-looking
statements. These forward-looking statements reflect the current beliefs and expectations of management and
include statements regarding the proposed terms of the proposed offerings, completion, timing and size of the proposed offerings and the
expected use of proceeds from the offerings. These statements are not guarantees of future performance and are subject to known
and unknown risks, uncertainties, and other factors, some of which are beyond the Company’s control, are difficult to predict, and
could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions
security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view
of the Company only as of the date of this announcement. Forward-looking statements are subject to risks
and uncertainties that may cause the Company’s actual activities or results to differ materially from those indicated or implied
by any forward-looking statement, including, without limitation, due to risks and uncertainties related to market conditions and the satisfaction
of closing conditions related to the proposed public offering, risks disclosed in the section titled “Risk Factors”
included in the preliminary prospectus supplement filed with the SEC on September 13, 2023, and risks disclosed in other documents OKYO
files from time to time with the SEC. The forward-looking statements made in this announcement relate only to events as of the
date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these
forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except
as required by law or by any appropriate regulatory authority.
Enquiries: |
|
|
|
|
|
|
|
|
|
OKYO Pharma Limited |
|
Gary S. Jacob, Chief Executive Officer |
|
+44 (0)20 7495 2379 |
|
|
|
|
|
Investor Relations |
|
Paul Spencer |
|
+44 (0)20 7495 2379
|
OKYO Pharma (NASDAQ:OKYO)
Historical Stock Chart
From Apr 2024 to May 2024
OKYO Pharma (NASDAQ:OKYO)
Historical Stock Chart
From May 2023 to May 2024